ECSP10010430A - Ciertas Entidades Químicas, Composiciones y Procedimientos - Google Patents
Ciertas Entidades Químicas, Composiciones y ProcedimientosInfo
- Publication number
- ECSP10010430A ECSP10010430A EC2010010430A ECSP10010430A ECSP10010430A EC SP10010430 A ECSP10010430 A EC SP10010430A EC 2010010430 A EC2010010430 A EC 2010010430A EC SP10010430 A ECSP10010430 A EC SP10010430A EC SP10010430 A ECSP10010430 A EC SP10010430A
- Authority
- EC
- Ecuador
- Prior art keywords
- skeletal
- muscle
- chemical entities
- certain chemical
- procedures
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000005829 chemical entities Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 210000003205 muscle Anatomy 0.000 abstract 2
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 208000036119 Frailty Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 102000003505 Myosin Human genes 0.000 abstract 1
- 108060008487 Myosin Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 102000013534 Troponin C Human genes 0.000 abstract 1
- 102000013394 Troponin I Human genes 0.000 abstract 1
- 108010065729 Troponin I Proteins 0.000 abstract 1
- 102000004987 Troponin T Human genes 0.000 abstract 1
- 108090001108 Troponin T Proteins 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 208000024980 claudication Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 210000002235 sarcomere Anatomy 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proveen ciertas entidades químicas y métodos de uso para modular la miosina esquelética, la actina del esqueleto, la tropomiosina del esqueleto, la troponina C del esqueleto, la troponina I esquelética, troponina T esquelética y el músculo esquelético, incluyendo fragmentos y las isoformas de la misma, así como el sarcómero esquelético, y métodos de uso en el tratamiento de los trastornos neuromusculares, condiciones que tienen pérdida de masa muscular, la claudicación, la fragilidad, el síndrome metabólico, la atrofia muscular asociada con el desuso, y la fatiga muscular, y otras indicaciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2606708P | 2008-02-04 | 2008-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010430A true ECSP10010430A (es) | 2011-02-28 |
Family
ID=40952391
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010430A ECSP10010430A (es) | 2008-02-04 | 2010-08-27 | Ciertas Entidades Químicas, Composiciones y Procedimientos |
| EC2010010432A ECSP10010432A (es) | 2008-02-04 | 2010-08-30 | Método para la mejora de la recuperación de hidrocarburos pesados |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010432A ECSP10010432A (es) | 2008-02-04 | 2010-08-30 | Método para la mejora de la recuperación de hidrocarburos pesados |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7989469B2 (es) |
| EP (1) | EP2244711A4 (es) |
| JP (1) | JP2011510985A (es) |
| KR (1) | KR20100119773A (es) |
| CN (1) | CN101983061A (es) |
| AR (1) | AR072242A1 (es) |
| AU (1) | AU2009210787A1 (es) |
| BR (1) | BRPI0907502A2 (es) |
| CA (1) | CA2713864A1 (es) |
| CL (1) | CL2009000246A1 (es) |
| CO (1) | CO6290673A2 (es) |
| EA (1) | EA201001224A1 (es) |
| EC (2) | ECSP10010430A (es) |
| IL (1) | IL207367A0 (es) |
| MX (1) | MX2010008518A (es) |
| TW (1) | TW200946524A (es) |
| WO (1) | WO2009099594A1 (es) |
| ZA (1) | ZA201005780B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| MX2010008518A (es) * | 2008-02-04 | 2010-11-10 | Cytokinetics Inc | Ciertas entidades quimicas, composiciones y metodos. |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| US8927572B2 (en) | 2011-07-09 | 2015-01-06 | Xuanzhu Pharma Co., Ltd. | Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof |
| WO2013010015A2 (en) | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Combination als therapy |
| CN104395458A (zh) * | 2012-04-11 | 2015-03-04 | 赛特凯恩蒂克公司 | 改善对骨骼肌疲劳的抵抗力 |
| EP3137622B1 (en) | 2014-04-29 | 2021-11-24 | Cytokinetics, Inc. | Methods of reducing decline in vital capacity |
| TW201927738A (zh) * | 2017-12-14 | 2019-07-16 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| TWI794369B (zh) * | 2017-12-14 | 2023-03-01 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| JP7592029B2 (ja) | 2019-05-28 | 2024-11-29 | マンカインド ファーマ リミテッド | ヤヌスキナーゼ１の阻害のための新規化合物 |
| KR20240024062A (ko) * | 2021-05-06 | 2024-02-23 | 엑스사이언티아 에이아이 리미티드 | Pkc-세타 조정제 |
| CN118702622A (zh) * | 2024-08-30 | 2024-09-27 | 阜新达得利化工股份有限公司 | 一种3-溴-2-氰基吡啶的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) * | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003294249A1 (en) | 2002-11-08 | 2004-06-03 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| US20060148805A1 (en) | 2003-07-01 | 2006-07-06 | Meng Hsin Chen | Opthalmic compositions for treating ocular hypertension |
| CA2550091A1 (en) | 2003-12-19 | 2005-07-07 | Elixir Pharmaceuticals, Inc. | Methods of treating a disorder |
| EP1715855A4 (en) | 2004-01-29 | 2010-06-16 | Elixir Pharmaceuticals Inc | ANTIVIRAL DRUGS |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1959962A2 (en) * | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| EP2666777A1 (en) | 2006-08-02 | 2013-11-27 | Cytokinetics, Inc. | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods |
| NZ576278A (en) | 2006-10-19 | 2011-12-22 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| WO2008075007A1 (en) * | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| EP2139478A4 (en) * | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| MX2010008518A (es) * | 2008-02-04 | 2010-11-10 | Cytokinetics Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
-
2009
- 2009-02-02 MX MX2010008518A patent/MX2010008518A/es not_active Application Discontinuation
- 2009-02-02 KR KR1020107018611A patent/KR20100119773A/ko not_active Withdrawn
- 2009-02-02 EP EP09708594A patent/EP2244711A4/en not_active Withdrawn
- 2009-02-02 AU AU2009210787A patent/AU2009210787A1/en not_active Abandoned
- 2009-02-02 US US12/364,394 patent/US7989469B2/en not_active Expired - Fee Related
- 2009-02-02 CA CA2713864A patent/CA2713864A1/en not_active Abandoned
- 2009-02-02 JP JP2010545031A patent/JP2011510985A/ja not_active Withdrawn
- 2009-02-02 WO PCT/US2009/000686 patent/WO2009099594A1/en not_active Ceased
- 2009-02-02 BR BRPI0907502A patent/BRPI0907502A2/pt not_active Application Discontinuation
- 2009-02-02 CN CN2009801121602A patent/CN101983061A/zh active Pending
- 2009-02-02 EA EA201001224A patent/EA201001224A1/ru unknown
- 2009-02-03 TW TW098103382A patent/TW200946524A/zh unknown
- 2009-02-04 CL CL2009000246A patent/CL2009000246A1/es unknown
- 2009-02-04 AR ARP090100372A patent/AR072242A1/es unknown
-
2010
- 2010-08-02 IL IL207367A patent/IL207367A0/en unknown
- 2010-08-13 ZA ZA2010/05780A patent/ZA201005780B/en unknown
- 2010-08-27 EC EC2010010430A patent/ECSP10010430A/es unknown
- 2010-08-30 EC EC2010010432A patent/ECSP10010432A/es unknown
- 2010-08-30 CO CO10106625A patent/CO6290673A2/es not_active Application Discontinuation
-
2011
- 2011-06-21 US US13/165,281 patent/US20110312975A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009210787A1 (en) | 2009-08-13 |
| ECSP10010432A (es) | 2011-01-31 |
| EP2244711A4 (en) | 2011-08-24 |
| CN101983061A (zh) | 2011-03-02 |
| CO6290673A2 (es) | 2011-06-20 |
| CL2009000246A1 (es) | 2009-06-26 |
| AR072242A1 (es) | 2010-08-18 |
| EA201001224A1 (ru) | 2011-08-30 |
| US7989469B2 (en) | 2011-08-02 |
| BRPI0907502A2 (pt) | 2019-01-15 |
| KR20100119773A (ko) | 2010-11-10 |
| MX2010008518A (es) | 2010-11-10 |
| TW200946524A (en) | 2009-11-16 |
| WO2009099594A1 (en) | 2009-08-13 |
| US20090253737A1 (en) | 2009-10-08 |
| JP2011510985A (ja) | 2011-04-07 |
| CA2713864A1 (en) | 2009-08-13 |
| EP2244711A1 (en) | 2010-11-03 |
| US20110312975A1 (en) | 2011-12-22 |
| IL207367A0 (en) | 2010-12-30 |
| ZA201005780B (en) | 2011-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010430A (es) | Ciertas Entidades Químicas, Composiciones y Procedimientos | |
| WO2008016648A3 (en) | Certain chemical entities, compositions and methods | |
| CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
| CL2008002916A1 (es) | Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros. | |
| CL2008001632A1 (es) | Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma. | |
| CO6362020A2 (es) | Mutantes fgf21 y uso de los mismos | |
| ECSP12012211A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BR112015024846A2 (pt) | composições para utilização no estímulo do crescimento ósseo | |
| MX357528B (es) | Metodos para el tratamiento de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales o influencias ambientales. | |
| EA201491666A1 (ru) | Способы повышения устойчивости скелетных мышц к утомлению | |
| AR073563A1 (es) | Terapia de combinacion para el tratamiento de diabetes y estados relacionados | |
| PE20150954A1 (es) | Proteinas del dominio de soporte basadas en fibronectina que se fijan a miostatina | |
| UY30454A1 (es) | Moduladores tiazolopirimidina de trpv1 | |
| CL2007002492A1 (es) | Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras. | |
| BR112014005358A2 (pt) | composição para alívio da dor, compreendendo um agonista seletivo de trpv1, e a sua fabricação e utilização | |
| CL2014000801A1 (es) | Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos. | |
| SV2010003556A (es) | Moleculas y metodos para modular el componente de complemento | |
| BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
| CO6690805A2 (es) | 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3 | |
| UY30468A1 (es) | Compuestos quimicos. | |
| MX2010001692A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| UY31540A1 (es) | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 | |
| ECSP088807A (es) | Tetrahidro-pirimidoazepinas como moduladores del potencial transitorio de receptor vaillinoide 1 (trpv1) | |
| BR112016007487A2 (pt) | composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica | |
| PH12014502711A1 (en) | Compositions and methods for enhancing mobilization and proliferation of blastomere-like stem cells |